May 10, 2023 11:17 AM EDT
Financing
Law

Botox com­peti­tor Daxxi­fy hits $15.4M in Q1 earn­ings as mak­er faces trade se­crets law­suit

Paul Schloesser

Associate Editor

The sec­ond round of rev­enue num­bers is in for Daxxi­fy, Re­vance Ther­a­peu­tics’ longer-last­ing cos­met­ic in­jec­tion set to com­pete against Ab­b­Vie’s Botox.

Re­vance Ther­a­peu­tics on Tues­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times